{"doi":"10.1001/jamanetworkopen.2021.44210","title":"In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence","abstract":"Importance: Electronic directly observed therapy (DOT) is used increasingly as an alternative to in-person DOT for monitoring tuberculosis treatment. Evidence supporting its efficacy is limited. Objective: To determine whether electronic DOT can attain a level of treatment observation as favorable as in-person DOT. Design, Setting, and Participants: This was a 2-period crossover, noninferiority trial with initial randomization to electronic or in-person DOT at the time outpatient tuberculosis treatment began. The trial enrolled 216 participants with physician-suspected or bacteriologically confirmed tuberculosis from July 2017 to October 2019 in 4 clinics operated by the New York City Health Department. Data analysis was conducted between March 2020 and April 2021. Interventions: Participants were asked to complete 20 medication doses using 1 DOT method, then switched methods for another 20 doses. With in-person therapy, participants chose clinic or community-based DOT; with electronic DOT, participants chose live video-conferencing or recorded videos. Main Outcomes and Measures: Difference between the percentage of medication doses participants were observed to completely ingest with in-person DOT and with electronic DOT. Noninferiority was demonstrated if the upper 95% confidence limit of the difference was 10% or less. We estimated the percentage of completed doses using a logistic mixed effects model, run in 4 modes: modified intention-to-treat, per-protocol, per-protocol with 85% or more of doses conforming to the randomization assignment, and empirical. Confidence intervals were estimated by bootstrapping (with 1000 replicates). Results: There were 173 participants in each crossover period (median age, 40 years [range, 16-86 years]; 140 [66%] men; 80 [37%] Asian and Pacific Islander, 43 [20%] Black, and 71 [33%] Hispanic individuals) evaluated with the model in the modified intention-to-treat analytic mode. The percentage of completed doses with in-person DOT was 87.2% (95% CI, 84.6%-89.9%) vs 89.8% (95% CI, 87.5%-92.1%) with electronic DOT. The percentage difference was -2.6% (95% CI, -4.8% to -0.3%), consistent with a conclusion of noninferiority. The 3 other analytic modes yielded equivalent conclusions, with percentage differences ranging from -4.9% to -1.9%. Conclusions and Relevance: In this trial, the percentage of completed doses under electronic DOT was noninferior to that under in-person DOT. This trial provides evidence supporting the efficacy of this digital adherence technology, and for the inclusion of electronic DOT in the standard of care. Trial Registration: ClinicalTrials.gov Identifier: NCT03266003.","journal":"JAMA Network Open","year":2022,"id":240121,"datarank":2.0007693076762223,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"self_citation_contribution":0.5775221402565088,"citation_network_contribution":1.4232471674197134,"self_endowment_contribution":0.5775221402565088,"citer_contribution":1.4232471674197134,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":40,"citers_with_citation_signal":31,"citers_with_endowment":31,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9564,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03266003"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":867242,"name":"Joan M. Mangan","orcid":"0000-0001-6770-086X","position":1,"is_corresponding":false},{"id":867243,"name":"Chee Kin Lam","orcid":"0000-0002-4821-4898","position":2,"is_corresponding":false},{"id":867244,"name":"Michelle Macaraig","orcid":"0000-0002-2891-9903","position":3,"is_corresponding":false},{"id":868001,"name":"Marco M. Salerno","orcid":null,"position":4,"is_corresponding":false},{"id":867245,"name":"B. Rey deCastro","orcid":"0000-0002-1610-5849","position":5,"is_corresponding":false},{"id":607693,"name":"Neela D. Goswami","orcid":"0000-0003-4508-9144","position":6,"is_corresponding":false},{"id":867246,"name":"Carol Y. Lin","orcid":"0000-0003-0223-2705","position":7,"is_corresponding":false},{"id":105380,"name":"Neil W. Schluger","orcid":"0000-0003-0162-2082","position":8,"is_corresponding":false},{"id":346884,"name":"Andrew Vernon","orcid":"0000-0003-1105-8534","position":9,"is_corresponding":false},{"id":868002,"name":"eDOT Study Team","orcid":null,"position":10,"is_corresponding":false},{"id":868003,"name":"Sapna Bamrah-Morris","orcid":null,"position":11,"is_corresponding":false},{"id":868004,"name":"Sheridan Bowers","orcid":null,"position":12,"is_corresponding":false},{"id":868005,"name":"Shannon Carberry","orcid":null,"position":13,"is_corresponding":false},{"id":867247,"name":"Christine Chuck","orcid":"0000-0001-9359-8491","position":14,"is_corresponding":false},{"id":868006,"name":"Matthew Dias","orcid":null,"position":15,"is_corresponding":false},{"id":867248,"name":"Grace Gao","orcid":"0000-0001-6109-7406","position":16,"is_corresponding":false},{"id":301786,"name":"Richard S. Garfein","orcid":"0000-0003-3663-7153","position":17,"is_corresponding":false},{"id":868007,"name":"Vernard Green","orcid":null,"position":18,"is_corresponding":false},{"id":868008,"name":"Lon Gross","orcid":null,"position":19,"is_corresponding":false},{"id":868009,"name":"Gary Henry","orcid":null,"position":20,"is_corresponding":false},{"id":868010,"name":"A. Ross Hill","orcid":null,"position":21,"is_corresponding":false},{"id":868011,"name":"Sarah Kiskadden-Bechtel","orcid":null,"position":22,"is_corresponding":false},{"id":868012,"name":"Meena Lakshman","orcid":null,"position":23,"is_corresponding":false},{"id":868013,"name":"Nikolaos Mitropoulos","orcid":null,"position":24,"is_corresponding":false},{"id":867249,"name":"Diana Nilsen","orcid":"0000-0001-7031-6615","position":25,"is_corresponding":false},{"id":868014,"name":"Margaret J. Oxtoby","orcid":null,"position":26,"is_corresponding":false},{"id":868015,"name":"Patrick P J Philips","orcid":null,"position":27,"is_corresponding":false},{"id":868016,"name":"Michael Reaves","orcid":null,"position":28,"is_corresponding":false},{"id":867250,"name":"Errol Robinson","orcid":"0000-0003-0696-6239","position":29,"is_corresponding":false},{"id":868017,"name":"Charlene Sathi","orcid":null,"position":30,"is_corresponding":false},{"id":867251,"name":"Brock Stewart","orcid":"0000-0002-3762-2108","position":31,"is_corresponding":false},{"id":867252,"name":"Anila Thomas","orcid":"0000-0001-6068-6639","position":32,"is_corresponding":false},{"id":868018,"name":"Zhanna Tolochko","orcid":null,"position":33,"is_corresponding":false},{"id":231950,"name":"Lisa Trieu","orcid":"0000-0002-6039-9223","position":34,"is_corresponding":false},{"id":771827,"name":"Carla A. Winston","orcid":"0000-0003-0261-966X","position":35,"is_corresponding":false},{"id":867241,"name":"Joseph Burzynski","orcid":"0000-0002-7109-7669","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T00:22:46.554789Z","pmid":"35050357","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}